ReviewFood science & nutrition2025
The Beneficial Effects of Berberine on Brain Functions in Age-Related Neurological Disorders: From Molecular Signaling to Treatment.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Berberine targets the PI3Kα LYS672 site to suppress the PI3K/Akt/NF-κB axis and modulate microglial functional states after intracerebral hemorrhage.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Targeting mitochondrial dysfunction and neuroprotection in neurodegenerative disorders: emerging therapeutic potential of berberine and polymeric nanoparticle-based delivery systems.Inflammopharmacology · 2026Review
- The Beneficial Effects of Berberine on Brain Functions in Age-Related Neurological Disorders: From Molecular Signaling to Treatment.Food science & nutrition · 2025Review
- In silico evaluation of berberine and silymarin against metabolic targets: a rationale for OMICS technology-based co-formulation.In silico pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR), a naturally occurring compound with diverse medicinal properties, is emerging as a compelling candidate for managing age-related central nervous system conditions. Preclinical studies have extensively explored its impact on neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease, revealing its capacity to modulate key pathological processes. Mechanistically, BBR is shown to mitigate neuroinflammation, oxidative stress, and endoplasmic reticulum stress, thereby reducing neuronal damage and apoptosis. While these mechanistic insights and preclinical data are robust, clinical evidence remains nascent, necessitating further rigorous investigation to fully understand BBR's therapeutic efficacy and translate its promise into clinical practice. This narrative review provides a comprehensive examination of BBR's application in treating neurological conditions, emphasizing its molecular signaling pathways and critically evaluating the current translational landscape. It also identifies promising directions for future research into BBR's neuroprotective roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.